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Abstract
Objective
To evaluate the performance of low contrast media (CM) dose dual-energy computed
tomography pulmonary angiography (CTPA) with advanced monoenergetic reconstructions
in patients with suspected pulmonary embolism (PE).
Materials and Methods
The study had institutional review board approval; all patients gave written informed con-
sent. Forty-one patients (25 men, 16 women, mean age 62.9±14.7 years) undergoing low
CM dose (15ml, 6g iodine) dual-energy CTPA with advanced monoenergetic reconstruc-
tions were matched via propensity-scoring based on logistic regression analysis with a com-
parison group of 41 patients (24 men, 17 women, mean age 62.7±13.9 years) undergoing
standard CM dose single-energy CTPA (80ml, 24g iodine). Subjective (noise, artifacts) and
objective (attenuation, noise, contrast-to-noise ratio (CNR)) image quality was assessed by
two blinded, independent readers. All patients underwent clinical follow-up after three
months for evaluation of adverse events.
Results
Interrater agreement for subjective image quality in both groups ranged from fair to excellent
(ICC: 0.46–0.84); agreement for objective image quality was excellent (ICC: 0.83–0.93).
There was no significant difference regarding subjective noise (p = 0.15–0.72) and artifacts
(p = 0.16–1) between the low and the standard CM dose group. There was no significant dif-
ference regarding CNR between the CM dose groups (p = 0.11–0.87). Seven of the 41
(17%) patients in the low and 5/41 (12%) in the standard CM dose group were diagnosed
with PE (p = 0.32). No patient suffered from subsequent PE or PE-associated death during
the follow-up period.
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Conclusion
Dual-energy CTPA with advanced monoenergetic reconstruction is feasible with 6g iodine
and allows for the diagnosis and safe exclusion of central, lobar, and segmental PE.
Introduction
Pulmonary embolism (PE) represents an emergency condition with an incidence of 60-70/
100’000 cases per year and a high associated mortality [1, 2]. Mortality is substantially higher
in patients with coexisting nephropathy [3], a common comorbidity in this patient population
as shown in the PIOPED II study where 19% of patients were excluded from contrast
enhanced computed tomography (CT) due to elevated serum creatinine levels [4].
The imaging method of choice for the diagnosis and exclusion of PE is CT pulmonary angi-
ography (CTPA), as it is widely available and has a high accuracy [5]. CTPA requires the intra-
venous administration of iodinated contrast media (CM), which has a potential nephrotoxic
effect particularly in patients with impaired kidney function who may develop contrast-
induced nephropathy (CIN) [6].
The causality of CIN after CM administration is controversially discussed in the litera-
ture. Several studies have shown that the risk of developing CIN is related to the volume of
intravenously administered iodinated CM [7, 8], and that there is no dose threshold below
which the administration of CM can be considered safe [9]. In distinction, other studies
found that CIN is only a risk factor in patients with elevated serum creatinine levels or even
suggest this phenomenon to be coincidental and unrelated to the administration of iodin-
ated CM [10, 11]. Still, the European Society or Urogenital Radiology (ESUR) currently rec-
ommends using the lowest possible amount of CM allowing for a definite diagnosis in
patients with impaired renal function or other associated risk factors [12]. Yet another rea-
son for reducing CM is the fact that iodine absorbs more ionizing radiation, which results
in an increased patient dose and hence, in a significant increase in the amount of DNA dou-
ble-strand breaks [13].
In the early era of multislice helical CT, a typical CTPA protocol required the adminis-
tration of 120 to 150 mL CM, equaling 30–42 g iodine [14–16]. Since then, several
advances in CT technology enabled the reduction of the amount of CM to 22–23 g iodine
[17, 18]. The introduction of conventional dual-energy CTPA showed potential for a fur-
ther reduction of the iodine load to 15–20 g [19]. A recently introduced algorithm in dual-
energy CT called advanced virtual monochromatic image reconstruction combines the
advantages of high attenuation at low energy levels with lower image noise at higher
energy levels [20, 21]. In a preliminary study in patients undergoing CTPA with 60 ml (18
g iodine), use of this algorithm resulted in a 1.8-fold increase of the contrast-to-noise ratio
(CNR) compared to conventional monoenergetic image reconstructions [22], suggesting
potential for further CM volume reduction. However, decreasing acquisition times in
combination with the use of low-kilovoltage protocols in state of the art CT angiography
require optimized CM injection protocols in order to achieve optimal image quality
[23–25].
The purpose of this study was to evaluate the performance of low CM dose dual-energy
CTPA with advanced monoenergetic reconstructions in patients with suspected PE. Our
hypothesis was that this algorithm would enable sufficient opacification of the pulmonary
arteries for the diagnosis and safe exclusion of PE with an iodine load of only 6 g.
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Materials and Methods
Patients
This study—including both a retrospective and a prospective part—had institutional review
board and local ethics committee approval (Kantonale Ethikkommission Zu¨rich). Written
informed consent was obtained from all patients in both study parts.
For the prospective, low CM dose group, a total of 101 in- and outpatients were screened
for inclusion over a 6-month period (from May to October 2015). The indication for CT in all
patients was clinically suspected PE. Exclusion criteria were severely impaired renal function
(defined as estimated glomerular filtration rate (eGFR) below 30 ml/min/1.73m2) (n = 0),
hypersensitivity to iodinated CM (n = 0), a body mass index (BMI) above 30 kg/m2 (n = 16),
or patients younger than 18 years (n = 3). The reason for excluding patients with a BMI>30
mg/m2 is the fact that dual-energy CT images in obese patients may be associated with exces-
sive noise [26]. Thus, 82/101 patients (81%) were included in the prospective study part and
underwent CTPA with a low CM dose. From those 82 patients, one patient (1%) had a non-
diagnostic CTPA examination due to motion artifacts, one patient (1%) due to vascular anom-
alies, and 15 patients (18%) had a non-diagnostic examination due to insufficient contrast in
the pulmonary arteries. In summary, 17 patients (21%) had non-diagnostic imaging and were
therefore excluded from further analysis. Finally, a total of 65 patients were included in the low
CM dose group (Fig 1).
The decision whether an examination was of diagnostic image quality or not was made by
the study conductor and the attending radiologist assessing each CTPA examination in con-
sensus. Visual criteria were a sufficient opacification of the pulmonary arteries from the pul-
monary trunk to the segmental level allowing to diagnose or to rule-out PE with a high degree
of confidence. If an examination was considered non-diagnostic, it was repeated by applying
our standard CM dose protocol with an amount reduced by 15 ml CM in order to not to
exceed the regularly administered standard dose of 80 ml, and patients were excluded from
further analysis.
Fig 1. Patient selection pathway and propensity score matching.
doi:10.1371/journal.pone.0167214.g001
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The prospective, low CM dose population was compared to another group of patients,
which we retrospectively included into this study. Here, 122 in- and outpatients were included
over a 9-month period (from August 2014 to April 2015). These patients were examined on
the same CT scanner but with our standard CM dose protocol. We applied equal exclusion cri-
teria to the retrospective study group: severely impaired renal function (n = 0), hypersensitivity
to iodinated CM (n = 0), a BMI above 30 kg/m2 (n = 32), and age under 18 years (n = 7).
Patients with a BMI above 30 kg/m2 were similarly excluded to obtain comparable study popu-
lations. 83/122 patients (68%) fulfilled these inclusion criteria. Eight of these 83 patients (9.6%)
had a non-diagnostic examination, seven (8.4%) were excluded due to insufficient opacifica-
tion of the pulmonary arteries and one (1.2%) due to severe motion artifacts. Thus, a total of
75 patients were finally included in the standard CM dose group (Fig 1).
We generated a propensity score (see statistical analysis section below), to match patients
one to one from each CM dose group. Patients without a matching partner were excluded as
previously shown [27]. By doing so, a total of 82 patients from both groups remained in the
study for comparison: 41 patients in the low CM dose group (25 men, 16 women; mean age
men 63.8±13.9 years, range 26–83 years; mean age women 61.5±16.3 years, range 27–89
years), and 41 patients in the standard CM dose group (24 men, 17 women; mean age men
64.8±13.3 years, range 42–88 years; mean age women 59.6±14.6 years, range 28–83 years).
Twenty of the 82 patients (24%) had an impaired renal function, defined as an eGFR between
30 and 60ml/min/1.73m2.
Clinical information and follow-up
Clinical and demographic data of all patients were extracted from the electronic patient rec-
ords. Laboratory information was extracted likewise, including eGFR data within one day
prior to CT.
Since we evaluated CTPA with a low CM dose, hereby putting the patient to a potential risk
of missing PE in case of non-sufficient opacification of the pulmonary arteries, we assessed the
validity of a negative CTPE scan in both CM dose groups by using a three-month clinical fol-
low-up strategy as previously shown [28, 29]. For this, we evaluated the occurrence of subse-
quent PE or PE-related deaths within 3 months after the initial CTPA examination. Most
patients had follow-up examinations at our hospital addressing this question and therefore the
information was retrieved from their electronic records. If there was no in-house follow-up
available, the patient’s referring physician was contacted to exclude PE-associated events.
CT data acquisition and contrast media protocol
All patients underwent CTPA on a third generation dual-source CT scanner (SOMATOM
Force, Siemens Medical Systems, Forchheim, Germany): the low CM dose group with dual-
energy (90/150SnkVp), the standard CM dose group with single-energy (100 kVp) with further
data acquisition parameters as shown in the S1 Table. The scanning direction was cranio-cau-
dal during mid-inspiratory breath-hold for approximately 10 seconds. Data acquisition was
timed with bolus tracking using a trigger set in the pulmonary trunk. In both groups, we used
a monophasic protocol and the CM was injected with a power injector (CT Expre´s, Swiss Med-
ical Care, Lausanne, Switzerland) in an antecubital vein. Prior to CM injection, vessel patency
was tested with a saline flush of 10 ml. The CM injection was followed by another saline flush
in both groups for keeping the bolus compact and for reducing residual CM in brachial and
central venous vessels.
In the standard CM dose group, we used our routine PE protocol and injected 80 ml
(iodine load 24 g) CM (Imeron 300, 300 mg J/ml, Bracco S.p.A, Milan, Italy) at 4 ml/sec.
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Current literature advocates for flow rates in CTPA not below 1.2 g iodine / second [30].
Though our reconstruction algorithm results in an almost twofold CNR increase, we
reduced the flow rate to 0.6 g iodine / second in the low CM dose group. This allows pro-
longing the injection time to 10 seconds which makes the protocol less vulnerable in terms
of bolus timing. In order to compensate for the slower flow rate we increased the iodine
concentration which results in a higher peak enhancement, which is most desirable for an
optimal arterial enhancement [31]. Following this, we injected 15 ml (iodine load 6 g) of a
high concentrated CM (Imeron 400, 400 mg J/ml, Bracco S.p.A, Milan, Italy) at 1.5 ml/sec
(see S1 Table). This low CM dose protocol was tested and validated in a small preliminary
group of 10 patients, which were not included into the actual study. By analyzing the bolus
tracking protocols in these 10 patients, we found 30 Hounsfield Units (HU) as the best
threshold for initiating the scan start.
CT image reconstruction
From each patient in the low CM dose group, advanced virtual monoenergetic images were
reconstructed at 40 keV using a dedicated application (Monoenergetic Plus Application Class)
and software (syngo.viaVA30, Siemens) because it has been demonstrated that image recon-
structions at 40 keV improve the contrast of dual-energy CTPA [22]. All images from both
groups were reconstructed with a slice thickness of 2 mm and an increment of 1.6 mm, using
advanced modeled iterative reconstruction (ADMIRE, strength level 3) and a medium soft tis-
sue convolution kernel (Bf40).
CT data analysis
All image data were sent to the local picture archive and communication system (PACS)
(Impax 6.5.5; Agfa HealthCare, Mortsel, Belgium) and were read on dedicated monitors
(Barco nio 3mp LED, Barco N.V., Kortrijk Belgium).
Subjective image quality concerning overall noise and perivascular artifacts of the pul-
monary trunk (PT), the right lower lobe pulmonary artery (RLLPA), the right inferior pul-
monary vein (RIPV), and the descending aorta as well as the superior vena cava (SVC) and
the brachiocephalic vein (BC) (on the side where the contrast media was administered)
were assessed in each dataset by two blinded, independent readers ([xx] and [yy] (blinded
for review)), with 6 and 4 years of experience in chest radiology) by using a four-point
Likert scale as previously shown [32]: A score of 0 represented complete or almost com-
plete absence of either noise / artifacts, a score of 1 represented mild noise / artifacts, a
score of 2 represented moderate noise / artifacts, and a score of 3 represented marked
noise / artifacts. Each image series was read with fixed window settings (width 600 HU;
level 150 HU).
Objective image quality was assessed by the same two readers ([xx] and [yy]) and as previ-
ously shown [22]: Attenuation (in HU) was measured in the PT, RLLPA, RIPV, and in the
descending aorta at the level of the left ventricle by placing a circular region of interest (ROI)
adapted to the vessel size in the center of the vessel. Furthermore, attenuation was measured in
the periscapular musculature in a homogeneous area, and the standard deviation of attenua-
tion was used as an indicator for image noise. CNR was calculated for each vessel as follows:
CNR ¼
attenuation vessel ½HU   attenuation muscle ½HU
image noise ½HU
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Statistical analysis
To limit the observational character of the study when including both a prospective and a retro-
spective study population and for reducing the effect of potential confounding, we performed a
propensity-score matching for the two study groups. For the computation of the propensity
score, the following variables were included into a logistic regression model: age, gender, BMI,
eGFR, Wells score, presence or absence of PE, dyspnea, chest pain, and reduced general state of
health (Table 1). The validity of logistic regression was assessed using the Hosmer-Lemeshow
test. After generating the propensity score, patients were matched one to one with a caliper of
0.2 on the logit scale using the package Matching in R (R Foundation for Statistical Computing,
Vienna, Austria). Patients without a matching partner were excluded (Fig 2).
Interrater agreement for both subjective and objective image quality was assessed using the
intra-class correlation coefficient (ICC). Values were interpreted as follows: <0.40, poor agree-
ment; 0.40–0.59, fair agreement; 0.60–0.74, good agreement; and >0.75, excellent agreement
(15). Comparisons regarding artifacts and subjective noise at the above mentioned locations
between the low and standard CM group were performed using the Fisher’s exact test. To test
for differences between objective measures in the low and the standard CM group Mann-
Whitney U test or—in normally distributed data—unpaired Student’s t-test were used. Occur-
rences of PE in the two groups were compared using the χ2-test. All two-tailed p-values below
0.05 were considered statistically significant. All analyses (except of the propensity score-
matching) were performed using the statistical software package SPSS (release 22.0 IBM SPSS
Statistics, Armonk, NY: IBM Corp.).
Results
Radiation dose
Median volume CT dose index (CTDIvol) was 5.9 mGy in the low CM dose group and 5.6
mGy in the SD dose group, with no significant differences between groups (p = 0.12–0.96).
Median dose-length product was 206 mGycm and effective dose was 2.9 mSv, and the median
size specific dose estimate was 7.5 mGy in the low CM dose group and 7.0 mGy in the standard
CM dose group.
Subjective image quality
Interrater agreement for subjective noise and artifacts ranged from fair to excellent (ICC 0.46–
0.84) for both groups and for each location.
Table 1. Propensity score-matched patient characteristics.
Patient characteristic Low CM dose group (n = 41) Standard CM dose group (n = 41) p-values
Sex ratio (men/women) 25 / 16 24 / 17 .82
Age (year) # 62.9 ± 14.7 62.7 ± 13.9 .95
Body mass index (kg/m2) # 24.3 ± 3.3 24.3 ± 4.1 .81
eGFR (ml/min) # 81.7 ± 20.0 77.3 ± 29.2 .48
Wells-Score # 1.1 ± 1.2 1.0 ± 1.1 .58
Dyspnea (yes/no) 14/27 13/28 .82
Chest pain (yes/no) 14/27 13/28 .82
Reduced general state of health (yes/no) 8/33 8/33 1.0
Pulmonary embolism (yes) 7/34 5/36 .54
#Data is expressed as mean ± standard deviation.
eGFR = estimated glomerular filtration rate.
doi:10.1371/journal.pone.0167214.t001
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Subjective image quality was good with both readers rating noise and artifacts as being
either absent (score 0) or mild (score 1), and rarely moderate (score 2) for each location in
both subgroups except of artifacts in the standard CM dose group in the SVC and brachioce-
phalic / subclavian vein and in the low CM dose group in the SVC. Here, artifacts were pre-
dominantly moderate (score 2) or marked (score 3) due to undiluted contrast media (Fig 3).
There were no significant differences between the low and the standard CM dose group
regarding subjective noise (low CM dose group: mean score 0.5±0.5 to 1.3±0.5; standard CM
dose group: 0.2±0.4 to 1.0±0.5, p = 0.15–0.72). There were also no significant differences
between groups regarding artifacts (low CM dose group: 0±0 to 0.7±0.8; standard CM dose
group: 0.1±0.3 to 1.8±0.7, p = 0.16–1). Representative image examples of patients from the low
CM dose group are provided in Figs 4 and 5.
Fig 2. Distribution of propensity scores in the study population.
doi:10.1371/journal.pone.0167214.g002
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Objective image quality
Interrater agreement for attenuation, noise and CNR was excellent in both groups (ICC 0.83–
0.93). Attenuation was equal in both groups at the level of the PT (p = 0.2) and higher in the
low compared to the standard CM dose group in the RLLPA and RIPV (both p = 0.001).
Attenuation in the aorta was higher in the standard CM dose group, however, without reach-
ing statistical significance (p = 0.051) (Fig 6A).
Mean noise in the low CM group was 16±3 HU (range 10–21 HU) compared to 11±3 HU
(range 7–22 HU) in the standard CM dose group, being not significantly different (p = 0.59).
CNR was slightly higher in the standard CM dose group in the PT and the aorta without
being statistically significant (both p = 0.11) whereas CNR in the RLLPA as well as in the RIPV
were similar for both groups (p = 0.87 and 0.84) (Table 2, Fig 6B).
Clinical follow-up
In total, 12/82 patients (14%) were diagnosed with PE: 7/41 (17%) in the low CM dose group
and 5/41 (12%) in the standard CM dose group, with no difference between groups (p = 0.32).
Also, clinical information at three months showed that no patient suffered from subsequent
PE or PE-associated death during the follow-up period.
Discussion
Impaired renal function represents a clinically relevant comorbidity among patients with sus-
picion of PE. In our study population, 24% of patients had a reduced eGFR (ranging between
30 and 60 ml/min/1.73m2) and 22% were 70 years or older, both risk factors for developing
CIN [8]. Since the risk of CIN is related to the dose of administered CM [7, 8], these patients
benefit from an examination with a reduced CM dose. By using advanced monoenergetic
reconstructions from dual-energy CT, we showed that in patients with a BMI below 30 kg/m2,
the iodine load for CTPA can be considerably reduced to 6 g, while the subjective and objective
image quality of the examination remains preserved. Most importantly, CTPA with the low
CM dose safely excluded PE in our low pretest probability population, as shown in the clinical
follow-up period of three months.
In general, a reduction of CM dose is often paralleled by a higher rate of non-diagnostic
examinations due to suboptimal vessel opacification. In this study, non-diagnostic scans in the
standard CM dose group occurred in 8% of patients, being in line with data reported in the lit-
erature [33]. In the low CM dose group, the frequency of non-diagnostic CTPA scans due to
suboptimal vessel opacification was higher (18%). The most probable reason for this is the
small CM bolus with a low peak enhancement and short plateau phase requiring a short scan
window. This is also reflected by the lower CNR in the vessels proximally and distally to the
pulmonary arteries and veins in the low as compared to the standard CM dose group found in
this study. Hence, optimal bolus timing is pivotal for a diagnostic examination with low CM
volumes and is more difficult to realize compared to a CM protocol with higher amounts of
CM [34].
Additional complicating factors are the variability of cardiac output and the Valsalva
maneuver resulting in a transient interruption of contrast potentially impacting on the
Fig 3. Distribution of artifacts (a) and subjective noise (b) between the low and the standard CM dose group. (low = low CM dose group,
std = standard CM dose group, PT = pulmonary trunk, RLLPA = right lower lobe pulmonary artery, RIPV = right inferior pulmonary vein,
SVC = superior vena cava, SC = subclavian vein, BC = brachiocephalic vein)
doi:10.1371/journal.pone.0167214.g003
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opacification of pulmonary arteries [35]. It is assumed that low CM dose protocols are more
susceptible to these factors as compared to those with a standard CM dose.
Besides the administration of CM, the exposure of patients to ionizing radiation with its
theoretical risk represents a continuous concern. Several techniques are available for achieving
a marked radiation dose reduction, including tube current modulation, tube voltage adapta-
tion and use of iterative image reconstruction techniques [36]. Using several of these tech-
niques, we achieved in our study population a considerably lower radiation dose exposure
(median CTDIvol 5.6–5.9 mGy in both groups, respectively) to that previously published using
the same CT scanner technology (CTDIvol 8.1 mGy) and a population with similar BMI (24.3
kg/m2 in our study compared to 25 kg/m2 in [37]. Of course, repetition of non-diagnostic
CTPA examinations in the low CM dose group resulted in a higher radiation exposure as well
as a higher CM dose in this subgroup of patients. It is necessary to point out though that the
total amount of CM in patients with repeated CTPA did not exceed but was that normally
administered in our standard CM dose protocol. Nevertheless, the application of the low CM
dose CTPA protocol shown here must be carefully evaluated before scanning.
In case of successful clinical implication with non-diagnostic rates comparable to standard
CM dose protocols, our approach might be particularly interesting for elderly patients with
suspected PE and concomitant kidney disease, focusing on preservation of the remaining kid-
ney function rather than on radiation dose saving.
In this feasibility study, we focused on central, lobar and segmental pulmonary arteries but
did not specifically assess subsegmental pulmonary arteries. The rational behind this is the fact
that–although current CT technology allows for making the diagnosis of subsegmental PE–
these imaging findings do not affect the patients’ outcome. Thus, peripheral embolic disease in
subsegmental arteries does not necessarily need treatment but has been implied with overdiag-
nosis having the adverse effect of overtreatment and unnecessary radiation exposure [38].
This study had several limitations. First, the study population used for comparison was
enrolled retrospectively. We addressed this issue by using propensity score-matching for mini-
mizing confounding. Second, to our knowledge the applied image reconstruction algorithm of
dual-energy CT data is currently offered by one vendor only, and generalizability of our results
to other CT scanners is thus limited. Third, we excluded patients with a BMI>30 kg/m2,
because previous studies reported impaired image quality because of high noise in dual-energy
CT of obese patients, caused by limited photon penetration of the low voltage tube [26]. How-
ever, it might be possible that third generation dual-source CT being characterized by a higher
tube power [39] could provide dual-energy images with sufficient quality also at a higher BMI.
Fourth, despite of blinding the readers could have noticed the type of image reconstruction
and hence, CM group during their qualitative and quantitative image read-out. This is related
to the fact the visual impression of dual-energy CT data sets differ from that of standard recon-
structions. Finally, our sample size in both groups is relatively small, and future studies should
include more patients in randomized, prospective trials to prove the validity of our results.
In conclusion, our study shows that with optimal CM bolus timing, CTPA with dual-energy
data acquisition in combination with advanced monoenergetic image reconstruction is feasible
with a low iodine dose of 6 g allowing for the diagnosis and safe exclusion of central, lobar and
Fig 4. 55-year-old male patient with dyspnea. Dual-energy CTPA with advanced monoenergetic image
reconstructions and administration of 6 g iodine shows good opacification of the pulmonary vasculature with
emboli in the right and left pulmonary arteries (arrows) (a) and in both lower lobe arteries (arrows) (b). Coronal
thick (30 mm) maximum intensity projection (MIP) reformation (c) demonstrates good opacification of the
pulmonary artery system to the segmental level.
doi:10.1371/journal.pone.0167214.g004
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Fig 5. 63-year-old male patient with chest pain and dyspnea. Dual-energy CTPA with advanced
monoenergetic image reconstructions and administration of 6 g iodine shows good opacification of the main
pulmonary trunk and arteries (a) and a clot at the segmental level of the left lower lobe (arrow) (b). Coronal
thick (30 mm) maximum intensity projection (MIP) reformation (c) demonstrates good opacification of the
pulmonary artery system to the segmental level.
doi:10.1371/journal.pone.0167214.g005
Fig 6. Mean values and standard deviation of attenuation (a) and contrast-to-noise ratio (CNR, b) at the different
locations. (CM = contrast media, PT = pulmonary trunk, RLLPA = right lower lobe pulmonary artery, RIPV = right
inferior pulmonary vein).
doi:10.1371/journal.pone.0167214.g006
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segmental PE. This could be particularly useful in patients with coexisting kidney disease in
which preservation of residual kidney function is mandatory.
Supporting Information
S1 Table. CT scanning and contrast media protocols
(DOCX)
Author Contributions
Conceptualization: AM HA.
Data curation: AM KH BS HA.
Formal analysis: AM MW BS HA.
Investigation: AM KH KM.
Methodology: AM HA.
Project administration: AM TF HA.
Resources: DK TF HA.
Supervision: DK TF HA.
Validation: KM TF.
Visualization: AM HA.
Writing – original draft: AM.
Writing – review & editing: KH KM MW BS DK TF HA.
References
1. Be˘lohla´vek J, Dytrych V, Linhart A. Pulmonary embolism, part I: Epidemiology, risk factors and risk
stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism.
Experimental & Clinical Cardiology. 2013; 18(2):129.
2. Streiff MB, Agnelli G, Connors JM, Crowther M, Eichinger S, Lopes R, et al. Guidance for the treatment
of deep vein thrombosis and pulmonary embolism. Journal of thrombosis and thrombolysis. 2016; 41
(1):32–67. doi: 10.1007/s11239-015-1317-0 PMID: 26780738
3. Odutayo A, Adhikari NK, Barton J, Burns KE, Friedrich JO, Klein D, et al. Epidemiology of acute kidney
injury in Canadian critical care units: a prospective cohort study. Canadian Journal of Anesthesia. 2012;
59(10):934–42. doi: 10.1007/s12630-012-9761-1 PMID: 22843289
4. Stein PD, Fowler SE, Goodman LR, Gottschalk A, Hales CA, Hull RD, et al. Multidetector computed
tomography for acute pulmonary embolism. The New England journal of medicine. 2006; 354
(22):2317–27. doi: 10.1056/NEJMoa052367 PMID: 16738268
Table 2. CNR in the low and in the standard CM dose group.
Low CM dose group Standard CM dose group p-values
CNR PT 22.8 ± 13.0 27.2 ± 12.0 p = 0.11
CNR RLLPA 27.6 ± 14.0 27.1 ± 10.4 p = 0.87
CNR RIPV 21.7 ± 10.5 21.4 ± 10.0 p = 0.84
CNR aorta 8.8 ± 7.3 16.1 ± 9.7 p = 0.11
CM = contrast media. CNR = contrast-to-noise ratio. PT = pulmonary trunk. RLLPA = right lower lobe pulmonary artery. RIPV = right inferior pulmonary vein.
doi:10.1371/journal.pone.0167214.t002
PLOS ONE | DOI:10.1371/journal.pone.0167214 December 1, 2016 14 / 16
5. Remy-Jardin M, Pistolesi M, Goodman LR, Gefter WB, Gottschalk A, Mayo JR, et al. Management of
Suspected Acute Pulmonary Embolism in the Era of CT Angiography: A Statement from the Fleischner
Society 1. Radiology. 2007; 245(2):315–29. doi: 10.1148/radiol.2452070397 PMID: 17848685
6. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk.
Kidney International Supplements. 2006;( 100):S11–5.
7. Beckett KR, Moriarity AK, Langer JM. Safe Use of Contrast Media: What the Radiologist Needs to
Know. Radiographics. 2015; 35(6):1738–50. doi: 10.1148/rg.2015150033 PMID: 26466182
8. Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK, et al. Contrast induced
nephropathy: updated ESUR contrast media safety committee guidelines. European radiology. 2011;
21(12):2527–41. doi: 10.1007/s00330-011-2225-0 PMID: 21866433
9. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients under-
going coronary angiography. The American Journal of Medicine. 1990; 89(5):615–20. PMID: 2239981
10. Davenport MS, Khalatbari S, Dillman JR, Cohan RH, Caoili EM, Ellis JH. Contrast material-induced
nephrotoxicity and intravenous low-osmolality iodinated contrast material. Radiology. 2013; 267(1):94–
105. PubMed Central PMCID: PMC3606541. doi: 10.1148/radiol.12121394 PMID: 23360737
11. McDonald RJ, McDonald JS, Bida JP, Carter RE, Fleming CJ, Misra S, et al. Intravenous contrast mate-
rial-induced nephropathy: causal or coincident phenomenon? Radiology. 2013; 267(1):106–18. doi: 10.
1148/radiol.12121823 PMID: 23360742
12. Thomsen HS, Webb JA. Appendix A: ESUR Guidelines on Contrast Media Version 8.1. Contrast
Media: Springer; 2014. p. 257–74.
13. Deinzer CK, Danova D, Kleb B, Klose KJ, Heverhagen JT. Influence of different iodinated contrast
media on the induction of DNA double-strand breaks after in vitro X-ray irradiation. Contrast media &
molecular imaging. 2014; 9(4):259–67.
14. Qanadli SD, Hajjam ME, Mesurolle B, Barre´ O, Bruckert Fd, Joseph T, et al. Pulmonary Embolism
Detection: Prospective Evaluation of Dual-Section Helical CT versus Selective Pulmonary Arteriogra-
phy in 157 Patients 1. Radiology. 2000; 217(2):447–55. doi: 10.1148/radiology.217.2.r00nv01447
PMID: 11058644
15. Ghaye B, Nchimi A, Noukoua CT, Dondelinger RF. Does multi-detector row CT pulmonary angiography
reduce the incremental value of indirect CT venography compared with single-detector row CT pulmo-
nary angiography? Radiology. 2006; 240(1):256–62. doi: 10.1148/radiol.2401050350 PMID: 16720870
16. Jones SE, Wittram C. The Indeterminate CT Pulmonary Angiogram: Imaging Characteristics and
Patient Clinical Outcome 1. Radiology. 2005; 237(1):329–37. doi: 10.1148/radiol.2371041520 PMID:
16183940
17. Szucs-Farkas Z, Kurmann L, Strautz T, Patak MA, Vock P, Schindera ST. Patient exposure and image
quality of low-dose pulmonary computed tomography angiography: comparison of 100- and 80-kVp pro-
tocols. Investigative radiology. 2008; 43(12):871–6. doi: 10.1097/RLI.0b013e3181875e86 PMID:
19002059
18. Sigal-Cinqualbre AB, Hennequin R, Abada HT, Chen X, Paul JF. Low-kilovoltage multi-detector row
chest CT in adults: feasibility and effect on image quality and iodine dose. Radiology. 2004; 231
(1):169–74. doi: 10.1148/radiol.2311030191 PMID: 15068946
19. Delesalle M-A, Pontana F, Duhamel A, Faivre J-B, Flohr T, Tacelli N, et al. Spectral optimization of
chest CT angiography with reduced iodine load: experience in 80 patients evaluated with dual-source,
dual-energy CT. Radiology. 2013; 267(1):256–66. doi: 10.1148/radiol.12120195 PMID: 23319663
20. Grant KL, Flohr TG, Krauss B, Sedlmair M, Thomas C, Schmidt B. Assessment of an advanced image-
based technique to calculate virtual monoenergetic computed tomographic images from a dual-energy
examination to improve contrast-to-noise ratio in examinations using iodinated contrast media. Investi-
gative radiology. 2014; 49(9):586–92. doi: 10.1097/RLI.0000000000000060 PMID: 24710203
21. Husarik DB, Gordic S, Desbiolles L, Krauss B, Leschka S, Wildermuth S, et al. Advanced virtual monoe-
nergetic computed tomography of hyperattenuating and hypoattenuating liver lesions: ex-vivo and
patient experience in various body sizes. Investigative radiology. 2015; 50(10):695–702. doi: 10.1097/
RLI.0000000000000171 PMID: 26002623
22. Meier A, Wurnig M, Desbiolles L, Leschka S, Frauenfelder T, Alkadhi H. Advanced virtual monoener-
getic images: improving the contrast of dual-energy CT pulmonary angiography. Clinical radiology.
2015; 70(11):1244–51. doi: 10.1016/j.crad.2015.06.094 PMID: 26231468
23. Lell MM, Jost G, Korporaal JG, Mahnken AH, Flohr TG, Uder M, et al. Optimizing contrast media injec-
tion protocols in state-of-the art computed tomographic angiography. Investigative radiology. 2015; 50
(3):161–7. doi: 10.1097/RLI.0000000000000119 PMID: 25478743
24. Nance JW Jr., Henzler T, Meyer M, Apfaltrer P, Braunagel M, Krissak R, et al. Optimization of contrast
material delivery for dual-energy computed tomography pulmonary angiography in patients with
PLOS ONE | DOI:10.1371/journal.pone.0167214 December 1, 2016 15 / 16
suspected pulmonary embolism. Investigative radiology. 2012; 47(1):78–84. doi: 10.1097/RLI.
0b013e31821a2142 PMID: 21577132
25. Higashigaito K, Husarik DB, Barthelmes J, Plass AR, Manka R, Maisano F, et al. Computed Tomogra-
phy Angiography of Coronary Artery Bypass Grafts: Low Contrast Media Volume Protocols Adapted to
Tube Voltage. Investigative radiology. 2016; 51(4):241–8. doi: 10.1097/RLI.0000000000000233 PMID:
26646307
26. Yu L, Primak AN, Liu X, McCollough CH. Image quality optimization and evaluation of linearly mixed
images in dual-source, dual-energy CT. Medical physics. 2009; 36(3):1019–24. doi: 10.1118/1.
3077921 PMID: 19378762
27. McDonald JS, McDonald RJ, Carter RE, Katzberg RW, Kallmes DF, Williamson EE. Risk of intravenous
contrast material–mediated acute kidney injury: a propensity score–matched study stratified by base-
line-estimated glomerular filtration rate. Radiology. 2014; 271(1):65–73. doi: 10.1148/radiol.13130775
PMID: 24475854
28. Quiroz R, Kucher N, Zou KH, Kipfmueller F, Costello P, Goldhaber SZ, et al. Clinical validity of a nega-
tive computed tomography scan in patients with suspected pulmonary embolism: a systematic review.
The Journal of the American Medical Association. 2005; 293(16):2012–7. doi: 10.1001/jama.293.16.
2012 PMID: 15855435
29. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. The Lancet. 2012;
379(9828):1835–46.
30. Hendriks BM, Kok M, Mihl C, Bekkers SC, Wildberger JE, Das M. Individually tailored contrast enhance-
ment in CT pulmonary angiography. The British Journal of Radiology. 2016; 89(1061):20150850. doi:
10.1259/bjr.20150850 PMID: 26689096
31. Weininger M, Barraza JM, Kemper CA, Kalafut JF, Costello P, Schoepf UJ. Cardiothoracic CT angiog-
raphy: current contrast medium delivery strategies. American Journal of Roentgenology. 2011; 196(3):
W260–W72. doi: 10.2214/AJR.10.5814 PMID: 21343473
32. Likert R. A technique for the measurement of attitudes. New York,1932. 55 p. p.
33. Torbicki A, Perrier A, Konstantinides S, Agnelli G, GalièN, Pruszczyk P, et al. Guidelines on the diagno-
sis and management of acute pulmonary embolism. European heart journal. 2008; 29(18):2276–315.
doi: 10.1093/eurheartj/ehn310 PMID: 18757870
34. Bae KT. Peak Contrast Enhancement in CT and MR Angiography: When Does It Occur and Why?
Pharmacokinetic Study in a Porcine Model 1. Radiology. 2003; 227(3):809–16. doi: 10.1148/radiol.
2273020102 PMID: 12702823
35. Gosselin MV, Rassner UA, Thieszen SL, Phillips J, Oki A. Contrast dynamics during CT pulmonary
angiogram: analysis of an inspiration associated artifact. Journal of thoracic imaging. 2004; 19(1):1–7.
PMID: 14712124
36. Saltybaeva N, Martini K, Frauenfelder T, Alkadhi H. Organ Dose and Attributable Cancer Risk in Lung
Cancer Screening with Low-Dose Computed Tomography. PloS one. 2016; 11(5):e0155722. PubMed
Central PMCID: PMC4874690. doi: 10.1371/journal.pone.0155722 PMID: 27203720
37. Sabel BO, Buric K, Karara N, Thierfelder KM, Dinkel J, Sommer WH, et al. High-Pitch CT Pulmonary
Angiography in Third Generation Dual-Source CT: Image Quality in an Unselected Patient Population.
PloS one. 2016; 11(2):e0146949. PubMed Central PMCID: PMC4752234. doi: 10.1371/journal.pone.
0146949 PMID: 26872262
38. Wiener RS, Schwartz LM, Woloshin S. When a test is too good: how CT pulmonary angiograms find pul-
monary emboli that do not need to be found. The British Medical Journal. 2013; 347:f3368. PubMed
Central PMCID: PMC4688549. doi: 10.1136/bmj.f3368 PMID: 23820021
39. Meinel FG, Canstein C, Schoepf UJ, Sedlmaier M, Schmidt B, Harris BS, et al. Image quality and radia-
tion dose of low tube voltage 3rd generation dual-source coronary CT angiography in obese patients: a
phantom study. European Radiology. 2014; 24(7):1643–50. doi: 10.1007/s00330-014-3194-x PMID:
24816937
PLOS ONE | DOI:10.1371/journal.pone.0167214 December 1, 2016 16 / 16
